Pioglitazone ameliorates methotrexate-induced renal endothelial dysfunction via amending detrimental changes in some antioxidant parameters, systemic cytokines and Fas production

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 139-150

  El Gowilly, Sahar M ^a   Helmy, Mai M ^a   El Gowelli, Hanan M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Endothelium; Kidney; Methotrexate; Pioglitazone

Indexed keywords

ACETYLCHOLINE; CATALASE; CREATININE; CYTOKINE; FAS ANTIGEN; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 6; ISOPRENALINE; METHOTREXATE; NITRATE; NITRITE; PIOGLITAZONE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOXIDANT; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL VACUOLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG POTENCY; ENZYME ACTIVITY; KIDNEY PERFUSION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TREATMENT DURATION; UREA BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM; WISTAR RAT;

ANIMALS; ANTIGENS, CD95; ANTIOXIDANTS; CYTOKINES; GLUTATHIONE; KIDNEY; KIDNEY DISEASES; MALE; MALONDIALDEHYDE; METHOTREXATE; OXIDATIVE STRESS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84947611996     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.07.002     Document Type: Article

References (97)

1. Abd-Elrahman K.S., El-Gowelli H.M., Saad E.I., Abdel-Galil A.G., El-Mas M.M. Role of PPAR gamma/nitric oxide synthasesignaling in the cyclosporine-induced attenuation of endothelium-depend entrenovascular vasodilation. J. Cardiovasc. Pharmacol. 2010, 56:195-202.
2. Abraham P., Kolli V.K., Rabi S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem. Funct. 2010, 28:426-433.
3. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
4. Al-Ali S.Y., Hassan I.M., Sadek S. Ultrastructural changes in rat livers perfused in vitro and in vivo with a high dose of methotrexate. Histol. Histopathol. 2005, 20:1131-1145.
5. Armagan A., Uzar E., Uz E., Yilmaz H.R., Kutluhan S., Koyuncuoglu H.R., Soyupek S., Cam H., Serel T.A. Caffeic acid phenethyl ester modulates methotrexate-induced oxidative stress in testes of rat. Hum. Exp. Toxicol. 2008, 27:547-552.
6. Asvadi I., Hajipour B., Asvadi A., Asl N.A., Roshangar L., Khodadadi A. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur. Rev. Med. Pharmacol. Sci. 2011, 15:1003-1009.
7. Babiak R.M., Campello A.P., Carnieri E.G., Oliveira M.B. Methotrexate: pentose cycle and oxidative stress. Cell Biochem. Funct. 1998, 16:283-293.
8. Bachmann S., Mundel P. Nitricoxide in the kidney: synthesis, localization, and function. Am. J. Kidney Dis. 1994, 24:112-129.
9. Behr G.A., Schnorr C.E., Simões-Pires A., da Motta L.L., Frey B.N., Moreira J.C. Increased cerebral oxidative damage and decreased antioxidant defenses in ovariectomized and sham-operated rats supplemented with vitamin A. Cell Biol. Toxicol. 2012, 28:317-330.
10. Benveniste E.N., Tang L.P., Law R.M. Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Int. J. Dev. Neurosci. 1995, 13:341-349.
11. Boey O., Van Hooland S., Woestenburg A., Van der Niepen P., Verbeelen D. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin. Belg. 2006, 61:166-169.
12. Bohlen H.G., Zhou X., Unthank J.L., Miller S.J., Bills R. Transfer of nitric oxide by blood from upstream to downstream resistance vessels causes microvascular dilation. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1337-H1346.
13. Bourke R.S., Chheda G., Bremer A., Watanabe O., Tower D.B. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res. 1975, 35:110-116.
14. Bozkurt M., Em S., Oktayoglu P., Turkcu G., Yuksel H., Sariyildiz M.A., Caglayan M., Batmaz I., Nas K., Bozkurt Y., Kuyumcu M. Carvacrol prevents methotrexate-induced renal oxidative injury and renal damage in rats. Clin. Invest. Med. 2014, 37:E19.
15. Bray T.M., Taylor C.G. Tissue glutathione, nutrition, and oxidative stress. Can. J. Physiol. Pharmacol. 1993, 71:746-751.
16. Causey M.W., Hoffer Z.S., Miller S.L., Huston L.J., Satterly S.A., Martin M., Stallings J.D. Microarray and functional cluster analysis implicates transforming growth factor beta1 in endothelial cell dysfunction in a swine hemorrhagic shock model. J. Surg. Res. 2011, 170:120-132.
17. Chelikani P., Fita I., Loewen P.C. Diversity of structures and properties among catalases. Cell. Mol. Life Sci. 2004, 61:192-208.
18. Chen J., Li D., Zhang X., Mehta J.L. Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone. J. Cardiovasc. Pharmacol. Ther. 2004, 9:35-41.
19. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J., Roth B., Cheng T., Tran M., Lee I.L., Melquist J., Bondaruk J., Majewski T., Zhang S., Pretzsch S., Baggerly K., Siefker-Radtke A., Czerniak B., Dinney C.P., McConkey D.J. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25:152-165.
20. Daigle I., Rückert B., Schnetzler G., Simon H.U. Induction of the IL-10genevia the fas receptor in monocytes-an anti-inflammatory mechanism in the absence of apoptosis. Eur. J. Immunol. 2000, 30:2991-2997.
21. Drury R.A.B., Wallington E.A. Carleton's Histological Techniques 1980, Oxford University Press, New York. 5th ed.
22. El Amrani M., Aidi S., Amarenco P. Cerebral ischemic events and anti-cancer therapy. Rev. Neurol. (Paris) 2003, 159:371-380.
23. El-Gowelli H.M., Abd-Elrahman K.S., Saad E.I., El-Gowilly S.M., Abdel-Galil A.G., El-Mas M.M. PPARγ dependence of cyclosporine-isoprenalinerenovascular interaction: roles of nitric oxide synthase and hemeoxygenase. J. Cardiovasc. Pharmacol. 2011, 58:173-180.
24. El-Gowilly S.M. Metoprolol ameliorates cyclosporine a-induced hypertension and nephrotoxicity in rats. J. Cardiovasc. Pharmacol. 2011, 58:639-646.
25. El-Gowilly S.M., Ghazal A.R., Gohar E.Y., El-Mas M.M. Exacerbation by nicotine of the cyclosporine A-induced impairment of beta-adrenoceptor-mediated renal vasodilation in rats. Clin. Exp. Pharmacol. Physiol. 2008, 35:1164-1171.
26. El-Mas M.M., El-Gowelli H.M., Abd-Elrahman K.S., Saad E.I., Abdel-Galil A.G., Abdel-Rahman A.A. Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. Biochem. Pharmacol. 2011, 81:526-533.
27. Feuers R.J., Weindruch R., Leakey J.E., Duffy P.H., Hart R.W. Increased effective activity of rat liver catalase by dietary restriction. Age (Omaha) 1997, 20:215-220.
28. Fuskevåg O.M., Kristiansen C., Olsen R., Aarbakke J., Lindal S. Microvascular perturbations in ratsreceiving the maximum tolerated dose of methotrexate or its major metabolite7-hydroxymethotrexate. Ultrastruct. Pathol. 2000, 24:325-332.
29. Ghosh J., Das J., Manna P., Sil P.C. Acetaminophen induced renal injury via oxidative stress and TNF-alpha production: therapeutic potential of arjunolic acid. Toxicology 2010, 268:8-18.
30. Gomes M.B. Glitazones and the metabolic syndrome: mechanism of action, pathophysiology and therapeutic indications. Arq. Bras. Endocrinol. Metabol. 2006, 50:271-280.
31. Gow A.J., Buerk D.G., Ischiropoulos H. A novel reaction mechanism for the formation of S-nitrosothiol in vivo. J. Biol. Chem. 1997, 272:2841-2845.
32. Grönroos M., Chen M., Jahnukainen T., Capitanio A., Aizman R.I., Celsi G. Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatr. Blood Cancer 2006, 46:624-629.
33. Guan Y., Breyer M.D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001, 60:14-30.
34. Guevara I., Iwanejko J., Dembinska-Kiec A., Pankiewicz J., Wanat A., Anna P., Golabek I., Bartus S., Malczewska-Malec M., Szczudlik A. Determination of nitrite/nitrate in human biological material by the simple Griess reaction. Clin. Chim. Acta 1998, 274:177-188.
35. Hao L.N., Zhang Y.Q., Shen Y.H., Wang Z.Y., Wang Y.H. Induciblenitricoxidesynthase and Fas/FasL with C3expression of mouse retinal pigment epithelial cells in response to stimulation by peroxynitrite and antagonism of puerarin. Chin. Med. J. (Engl.) 2011, 124:2522-2529.
36. Hayashi Y., Abe M., Murai A., Shimizu N., Okamoto I., Katsuragi T., Tanaka K. Comparison of effects of nitric oxide synthase (NOS) inhibitors on plasma nitrite/nitrate levels and tissue NOS activity in septic organs. Microbiol. Immunol. 2005, 49:139-147.
37. Helmig S., Stephan P., Döhrel J., Schneider J. TNF-α mRNAexpressioncorrelates with TGF-β mRNAexpression, in vivo. Inflammation 2011, 34:255-259.
38. Helmy M.M., El-Gowelli H.M. Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production. Eur. J. Pharmacol. 2012, 683:294-300.
39. A receptor/lipid peroxides/COX-2/TGF-β1 signaling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats. Br. J. Pharmacol. 2015, (May 25). 10.1111/bph.13199.
40. Hensler T., Sauerland S., Riess P., Hess S., Helling H.J., Andermahr J., Bouillon B., Neugebauer E.A. The effect of additional brain injury on systemic interleukin (IL)-10 and IL-13 levels in trauma patients. Inflamm. Res. 2000, 49:524-528.
41. Ibrahim M.A., El-Sheikh A.A., Khalaf H.M., Abdelrahman A.M. Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity. Immunopharmacol. Immunotoxicol. 2014, 36:130-137.
42. Isoda T., Ito S., Kajiwara M., Nagasawa M. Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment. Pediatr. Int. 2007, 49:1018-1019.
43. Kaneko M., Elimban V., Dhalla N.S. Mechanism for depression of heart sarcolemmal Ca2+ pump by oxygen free radicals. Am. J. Physiol. 1989, 257:H804-H811.
44. Koca O., Gökçe A.M., Öztürk M.I., Ercan F., Yurdakul N., Karaman M.I. Effects of intensive cell phone (Philips Genic 900) use on the rat kidney tissue. Urol. J. 2013, 10:886-891.
45. Kolli V.K., Abraham P., Isaac B., Selvakumar D. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 2009, 55:83-90.
46. Kolli V.K., Abraham P., Rabi S. Methotrexate-induced nitrosative stress may play a critical role in small intestinal damage in the rat. Arch. Toxicol. 2008, 82:763-770.
47. Kotani N., Fukuo K., Yasuda O., Sugimoto K., Katuya T., Takemura Y., Kawamoto H., Yokoi T., Suzuki A., Ogihara T. Fas ligand mRNA levels of circulating leukocytes reflect endothelial dysfunction in hyperlipidemic but not in non-hyperlipidemic patients. Hypertens. Res. 2006, 29:217-225.
48. Kristensen L.O., Weismann K., Hutters L. Renal function and the rate of disappearance of methotrexate from serum. Eur. J. Clin. Pharmacol. 1975, 8:439-444.
49. Lajevardi V., Hallaji Z., Daklan S., Abedini R., Goodarzi A., Abdolreza M. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int. J. Dermatol. 2015, 54:95-101.
50. Landry A.P., Ding H. Redox control of human mitochondrial outer membrane protein MitoNEET [2Fe-2S] clusters by biological thiols and hydrogen peroxide. J. Biol. Chem. 2014, 289:4307-4315.
51. Lee K.W., Blann A.D., Lip G.Y. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Int. J. Cardiol. 2006, 111:302-308.
52. Lee T., Chau L. Fas/Fas ligand-mediated death pathway is involved in ox LDL-induced apoptosis in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2001, 280:C709-C718.
53. Legrand M., Kandil A., Payen D., Ince C. Effects of sepiapterin infusion on renal oxygenation and early acute renal injury after suprarenal aortic clamping in rats. J. Cardiovasc. Pharmacol. 2011, 58:192-198.
54. Levin D., Bell S., Sund R., Hartikainen S.A., Tuomilehto J., Pukkala E., Keskimäki I., Badrick E., Renehan A.G., Buchan I.E., Bowker S.L., Minhas-Sandhu J.K., Zafari Z., Marra C., Johnson J.A., Stricker B.H., Uitterlinden A.G., Hofman A., Ruiter R., de Keyse r C.E., MacDonald T.M., Wild S.H., McKeigue P.M., Colhoun H.M., Scottish Diabetes Research Network Epidemiology Group, Diabetes and Cancer Research Consortium Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015, 58:493-504.
55. López-Ongil S., Hernández-Perera O., Navarro-Antolín J., Pérez de Lema G., Rodríguez-Puyol M., Lamas S., Rodríguez-Puyol D. Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br. J. Pharmacol. 1998, 124:447-454.
56. Mahmoud M.F., El-Shazly S.M. Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines. Food Chem. Toxicol. 2013, 51:114-122.
57. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin. Chim. Acta 2010, 411:1412-1420.
58. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 1974, 47:469-474.
59. Matsumoto T., Noguchi E., Kobayashi T., Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic. Biol. Med. 2007, 42:993-1007.
60. McGuire J.J. Anticancer antifolates: current status and future directions. Curr. Pharm. Des. 2003, 9:2593-2613.
61. Medan D., Wang L., Toledo D., Lu B., Stehlik C., Jiang B.H., Shi X., Rojanasakul Y. Regulation of Fas (CD95)-induced apoptotic and necrotic cell death by reactive oxygen species in macrophages. J. Cell. Physiol. 2005, 203:78-84.
62. Merkle C.J., Moore I.M., Penton B.S., Torres B.J., Cueny R.K., Schaeffer R.C., Montgomery D.W. Methotrexate causes apoptosis in post mitotic endothelial cells. Biol. Res. Nurs. 2000, 2:5-14.
63. Morató L., Galino J., Ruiz M., Calingasan N.Y., Starkov A.A., Dumont M., Naudí A., Martínez J.J., Aubourg P., Portero-Otín M., Pamplona R., Galea E., Beal M.F., Ferrer I., Fourcade S., Pujol A. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain 2013, 136:2432-2443.
64. Murdaca G., Spanò F., Cagnati P., Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. Redox Rep. 2013, 18:95-99.
65. Mustak M., Boltuch-Sherif J., Horvath-Mechtler B., Kowalski-Bodzenta J., Erlacher L. Autoimmune pancreatitis associated with rheumatoid arthritis: successful combination therapy with steroids and methotrexate. Dtsch. Med. Wochenschr. 2011, 136:1842-1844.
66. Navarro-Antolín J., López-Muñoz M.J., Soria J., Lamas S. Superoxide limits cyclosporine-A-induced formation of peroxynitrite in endothelial cells(2). Free Radic. Biol. Med. 2002, 32:702-711.
67. Navarro-Antolín J., Redondo-Horcajo M., Zaragoza C., Alvarez-Barrientos A., Fernández A.P., León-Gómez E., Rodrigo J., Lamas S. Role of peroxynitrite in endothelial damage mediated by cyclosporine A. Free Radic. Biol. Med. 2007, 42:394-403.
68. Ng E.S., Cheng Z.J., Ellis A., Ding H., Jiang Y., Li Y., Hollenberg M.D., Triggle C.R. Nitrosothiol stores in vascular tissue: modulation by ultraviolet light, acetylcholine and ionomycin. Eur. J. Pharmacol. 2007, 560:183-192.
69. Niewczas M.A., Ficociello L.H., Johnson A.C., Walker W., Rosolowsky E.T., Roshan B., Warram J.H., Krolewski A.S. Serum concentrations of markers of TNF alpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 2009, 4:62-70.
70. Okada K., Yamashita U., Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res. 2006, 1102:175-178.
71. Ottolenghi A. 2-thiobarbituric acid (TBA) method. Arch. Biochem. Biophys. 1959, 77:355-360.
72. Pall M.L. Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO- cycle. Med. Hypotheses 2007, 69:821-825.
73. Parker R.A., Huang Q., Tesfamariam B. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 2003, 169:19-29.
74. Pérez-Girón J.V., Palacios R., Martín A., Hernanz R., Aguado A., Martínez-Revelles S., Barrús M.T., Salaices M., Alonso M.J. Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H1582-H1593.
75. Perianayagam M.C., Murray S.L., Balakrishnan V.S., Guo D., King A.J., Pereira B.J., Jaber B.L. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure. J. Lab. Clin. Med. 2000, 136:320-327.
76. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 2004, 22:929-979.
77. Quinn C.E., Lockhart C.J., Hamilton P.K., Loughrey C.M., McVeigh G.E. Effect of pioglitazone on endothelial function in impaired glucose tolerance. Diabetes Obes. Metab. 2010, 12:709-715.
78. Ramamoorthy S.K., Hephziba R. Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic acid and high flux dialysis. Indian J. Hematol. Blood Transfus. 2013, 29:90-92.
79. Reel B., Guzeloglu M., Bagriyanik A., Atmaca S., Aykut K., Albayrak G., Hazan E. The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats. J. Surg. Res. 2013, 182:176-184.
80. Richardson R.J., Murphy S.D. Effect of glutathione depletion on tissue deposition of methyl mercury in rats. Toxicol. Appl. Pharmacol. 1975, 31:505-519.
81. Roy S., Dontamalla S.K., Mondru A.K., Sannigrahi S., Veerareddy P.R. Downregulation of apoptosis and modulation of TGF-β1 by sodiumselenatepreventsstreptozotocin-induceddiabeticratrenalimpairment. Biol. Trace Elem. Res. 2011, 139:55-71.
82. Rubin R., Farber J.L. Mechanisms of the killing of cultured hepatocytes by hydrogen peroxide. Arch. Biochem. Biophys. 1984, 228:450-459.
83. Ryder R.E. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet. Med. 2015, 32:305-313.
84. Sakac V., Sakac M. Free oxygen radiacals and kidney diseases-part I. Med. Pregl. 2000, 53:463-474.
85. Sekse I., Iversen B.M., Daha M.R., Ofstad J. Acute effect of passive Heymann nephritis on renal blood flow and glomerular filtration rate in the rat: role of the anaphylatoxinC5a and the alpha-adrenergic nervous system. Nephron 1992, 60:453-459.
86. Shahin D., Toraby E.E., Abdel-Malek H., Boshra V., Elsamanoudy A.Z., Shaheen D. Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). Clin. Med. Insights Arthritis Musculoskelet. Disord. 2011, 4:1-10.
87. Shimizu S., Shiota K., Yamamoto S., Miyasaka Y., Ishii M., Watabe T., Nishida M., Mori Y., Yamamoto T., Kiuchi Y. Hydrogen peroxide stimulates tetrahydrobiopterin synthesis through the induction of GTP-cyclohydrolase I and increases nitric oxide synthase activity in vascular endothelial cells. Free Radic. Biol. Med. 2003, 34:1343-1352.
88. Stensballe J., Christiansen M., TÃnnesen E., Espersen K., Lippert F.K., Rasmussen L.S. The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality. Acta Anaesthesiol. Scand. 2009, 53:515-521.
89. Takemura Y., Fukuo K., Yasuda O., Inoue T., Inomata N., Yokoi T., Kawamoto H., Suhara T., Ogihara T. FassignalinginducesAktactivation and upregulation of endothelial nitric oxide synthase expression. Hypertension 2004, 43:880-884.
90. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 1969, 27:502-522.
91. Vardi N., Parlakpinar H., Ates B., Cetin A., Otlu A. The protective effects of Prunus armeniaca L (apricot) against methotrexate-induced oxidative damage and apoptosis in rat kidney. J. Physiol. Biochem. 2013, 69:371-381.
92. Vijay S.K., Mishra M., Kumar H., Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 2009, 46:27-33.
93. Wang L., Azad N., Kongkaneramit L., Chen F., Lu Y., Jiang B.H., Rojanasakul Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibit oryprotein down-regulation. J. Immunol. 2008, 180:3072-3080.
94. Witting P.K., Rayner B.S., Wu B.J., Ellis N.A., Stocker R. Hydrogen peroxide promotes endothelial dysfunction by stimulating multiple sources of superoxide anion radical production and decreasing nitric oxide bioavailability. Cell. Physiol. Biochem. 2007, 20:255-268.
95. Yamane D., Nagai M., Ogawa Y., Tohya Y., Akashi H. Enhancement of apoptosis via an extrinsic factor, TNF-alpha, in cells infected with cytopathic bovine viral diarrhea virus. Microbes Infect. 2005, 7:1482-1491.
96. Yarlagadda S.G., Perazella M.A. Drug-induced crystal nephropathy: an update. Expert Opin. Drug Saf. 2008, 7:147-158.
97. Zeng L., Yan Z., Ding S., Xu K., Wang L. Endothelial injury, an intriguing effect of methotrexate and cyclophosphamide during hematopoietic stem cell transplantation in mice. Transplant. Proc. 2008, 40:2670-2673.